|
Parameters
|
All (n=1178)
|
HFpEF# (n=513)
|
Non-HF# (n=665)
|
P value*
|
|---|
|
Age at evaluation (years)
|
49±14
|
50±14
|
48±14
|
0.146
|
|
Female
|
415 (35.2)
|
229 (44.6)
|
186 (28.0)
|
< 0.001
|
|
MWT (mm)
|
23 (20–26)
|
24 (21–28)
|
22 (19–25)
|
< 0.001
|
|
LVEF (%)
|
68±8
|
69±7
|
68±6
|
0.027
|
|
LVedd (mm)
|
44±6
|
43±6
|
44±5
|
< 0.001
|
|
Unexplained syncope
|
149 (12.6)
|
75 (14.6)
|
74 (11.1)
|
0.070
|
|
Atrial fibrillation
|
230 (19.5)
|
140 (27.3)
|
90 (13.5)
|
< 0.001
|
|
Maximal LVOT gradient
|
44 (10–80)
|
64 (29–94)
|
25 (8–67)
|
< 0.001
|
|
NT-proBNP
|
988.0 (494.1–1934.4)
|
1807.0 (1225.0–2892.6)
|
536.8 (304.6–796.8)
|
< 0.001
|
|
NYHA class
| | | | |
|
I
|
385 (32.7)
|
0 (0.0)
|
385 (57.9)
|
< 0.001
|
|
II
|
514 (43.6)
|
313 (61.0)
|
201 (30.2)
|
< 0.001
|
|
III/IV
|
279 (23.7)
|
200 (39.0)
|
79 (11.9)
|
< 0.001
|
|
Medicine treatment
| | | | |
|
Beta-blockers
|
861 (73.1)
|
387 (75.4)
|
474 (71.3)
|
0.110
|
|
ACEI/ARBs
|
232 (19.7)
|
70 (13.6)
|
162 (24.4)
|
< 0.001
|
|
Calcium-channel blocker
|
230 (19.5)
|
87 (17.0)
|
143 (21.5)
|
0.051
|
|
Diuretic
|
269 (22.8)
|
160 (31.2)
|
109 (16.4)
|
< 0.001
|
- In our cohort, the data on the maximal LVOT gradient were not available in 15 (1.3%) patients and the missing values were imputed using the median.
- Values are presented as the mean±SD, median (interquartile range) or n (%)
- AHA American Heart Association, LVedd left ventricular end-diastolic dimension, LVEF left ventricular ejection fraction, LVOT left ventricular outflow tract, MWT maximal wall thickness, NT-proBNP N-terminal pro-brain natriuretic peptide, NYHA New York Heart Association
- #Heart failure phenotypes were identified using AHA criteria
- *Comparison between patients with HFpEF and non-HF patients
